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INTRODUCTION
Glycogen storage disease type 1b (GSD-1b, MIM 232220)
is an autosomal recessive disease caused by a deficiency of
microsomal glucose-6-phosphate translocase (G6PT). This
protein transports glucose-6-phosphate into the endoplasmic
reticulum, where the enzyme glucose-6-phosphatase (G6Pase;
EC 3.1.3.9) converts glucose-6-phosphate into glucose and
inorganic phosphate. In 1997, Gerin et al. found that a gene
coding for the G6PT was mutated in GSD-1b (1). This gene,
SLC37A4 (formerly called as G6PT1), is located on chromo-
some 11q23.3 and encodes a protein with 429 amino acids
(1, 2). Apart from GSD-1b, mutations in the SLC37A4 gene
were also found in essentially all patients previously classified
as GSD 1c (2, 3) and 1d (4). Owing to the discovery, GSD-1b,
-1c, or -1d can be diagnosed by the direct mutation analysis
of the SLC37A4 gene, which can spare the patients from inva-
sive liver biopsy. In addition, the genetic causes in a family
can facilitate family screening and is essential for prenatal diag-
nosis (5). Recently, we experienced a Korean patient with typi-
cal clinical features of GSD-1b and performed a mutation
analysis to detect the SLC37A4 gene mutations. In this report,
we present the result of the mutation analysis in this patient.
CASE REPORT
The proband was the first child of non-consanguineous
Korean parents. He presented at age 12 yr for failure to thrive
and protuberant abdomen. His height and weight was below
the third percentile. Physical examination showed an enlarged
liver, which was 7 cm below the costal margin. Fasting blood
glucose was 40 mg/dL (reference interval: 70-110 mg/dL),
blood lactate 5.6 mg/dL (reference interval: 0.7-2.5 mg/dL),
serum uric acid 13.1 mg/dL (reference interval: 3.0-8.3 mg/
dL), and serum triglyceride 586 mg/dL (reference interval:
50-200 mg/dL). Liver function was within normal limit except
a mild elevation of serum ALT 65 U/L (reference interval:
<40 U/L). A glucose-loading test (1.75 g/kg) resulted in rapid
decrease in blood lactate and pyruvate. The neutrophil count
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A Novel Mutation (A148V) in the Glucose 6-phosphate Translocase
(SLC37A4) Gene in a Korean Patient with Glycogen Storage Disease
Type 1b
We report a Korean patient with glycogen storage disease type 1b (GSD-1b) whose
diagnosis was confirmed by liver biopsy and laboratory results. The patient presented
with delay of puberty and short stature on admission and had typical clinical symp-
toms of GSD as well as chronic neutropenia and inflammatory bowel disease. Mutation
analysis of the glucose 6-phosphate translocase 6-phosphate translocase (SLC37A4)
gene revealed that the patient was a compound heterozygote of two different muta-
tions including a deletion mutation (c.1042_1043delCT; L348fs) and a missense
mutation (A148V). The L348fs mutation was inherited from the patient’s father and
has been reported in an Italian family with GSD-1b, while the A148V mutation was
transmitted from the patient’s mother and was a novel mutation. To the best of our
knowledge, this is the first report of genetically confirmed case of GSD-1b in Korean.
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of the peripheral blood ranged from 0.4×109/L to 0.8×109/L
(reference interval: 1.5-9.0×109/L). He had experienced pro-
tracted diarrhea and recurrent perianal abscess. On colono-
scopic finding, he had an inflammatory bowel disease. He
underwent a liver biopsy in suspect of GSD. The biopsy show-
ed an increased glycogen contents (12.3%; reference interval:
1-6%/wet liver), which is compatible to GSD. The G6Pase
activities were measured with glucose-6-phosphate as sub-
strate and were incubated in a reaction mixture containing
0.25 M saccharose and 5 mM EDTA buffer, pH 7.2. Micro-
some permeabilized with sonification and at least two G6P
uptake studies were performed for each microsomal prepa-
ration. The patient’s G6Pase activities in liver homogenates
showed a very low level, 0.18 and 0.41 (normal range; 5.9-
93.0 nM/min/mg protein) in intact microsome and disrupted
microsome by sonification, respectively. Based on the clinical
and laboratory findings, GSD-1b was considered. But G6Pase
activity in disrupted microsome was a very low level, 0.41,
but approximately approximately 2.3 times elevated level than
that in untreated microsomes. In the first place, we had muta-
tional analysis of the G6Pase gene to exclude GSD-1a and ob-
served no mutation. We then analyzed mutations of SLC37A4
gene because we suspected clinically GSD-1b.
Genomic DNA was extracted from whole blood using a
Wizard genomic DNA purification kit according to the man-
ufacturer’s instruction (Promega, Madison, WI, U.S.A.). In-
formed consent was obtained from the parents. All the exons
and intron-exon boundaries of the SLC37A4 gene were ampli-
fied as described previously (3). Direct sequencing of PCR
products was performed on both forward and reverse strands
using the same primers for PCR and cycle sequencing was
performed with a BigDye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems, Foster City, CA, U.S.A.)
on the ABI 3,100 Genetic Analyzer (Applied Biosystems).
The sequence was compared with the reference sequence
NM_001467 in the National Center for Biotechnology Infor-
mation database (http://www.ncbi.nlm.nih.gov).
Two different mutations in the SLC37A4 gene were iden-
tified in the proband. One was a heterozygous deletion muta-
tion (c.1042_1043delCT; L348fsX400) in exon 8 and the
other was a heterozygous 1-bp substitution mutation (c.443C>
T; A148V) in exon 3 of the SLC37A4 gene. No other poly-
morphism was found in the sequencing results. The first
mutation, c.1042_1043delCT, has been previously reported
in an Italian family with GSD-1b (6). The second one is a
novel mutation, c443C>T, leading to substitution of alanine
by valine at codon 148 (A148V) (Fig. 1). The mother is het-
erozygous for the A148V mutation and the father is heterozy-
gous for the L348fs mutation. The A148V mutation has been
screened in 100 normal chromosomes and none had the same
mutation.
DISCUSSION
GSD1 or von Gierke disease includes a clinically, biochemi-
cally, and genetically heterogeneous group of autosomal reces-
sive disorders (7). The basic defects reside in the impairment
of the terminal steps of glycogenolysis and gluconeogenesis,
at different levels. Mutations of the glucose-6-phosphatase
gene (G6Pase), which lead to the enzyme deficiency, are res-
ponsible for the most frequent form of GSD 1, the subtype
1a (7). This gene is not mutated in patients in which there are
biochemical evidences of defects in the glucose-6-phosphate
transport system (8). GSD 1 patients diagnosed as non 1a have
been subdivided at least in 1b and 1c subtypes on the basis
of clinical and biochemical parameters (7). In GSD -1a, the
WBC count is generally within reference ranges because leuko-
cyte function is unaffected by the defect. In contrast, GSD-1b
causes chronic neutropenia due to the impaired function of
the neutrophils, particularly in relation to Gram-positive organ-
isms (9). In GSD-1b, a liver biopsy in which the hepatocytes
and their microsomes are intact shows deficient G6Pase activity
in enzyme assay, as the defects in the glucose-6-phosphate
transport system dose not deliver the required substrate into
the microsomal lumen. However, microsomes disrupted by
solubilization show normal glucose-6-phosphatase activity,
because all substrates have free entry to the enzyme. But G6-
Pase activity in disrupted microsome by sonification showed
a very low level in our enzyme assay, which was not compatible
finding to GSD-1b. Since liver biopsy specimen was not left,
we could not try to repeat the G6Pase enzyme assay. Our
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Fig. 1. Identification of SLC37A4 gene mutations. (A) Direct sequ-
encing analysis demonstrated a heterozygous C to T transition
(arrow; c.443C>T) resulting in a A148V missense mutation was
observed in exon 3. (B) A heterozygous 2-bp deletion (arrow; c.1042-
1043delCT) resulting in a A347fs×400 mutation in exon 8. Because
the sequencing was performed with an anti-sense primer, over-
lapped peaks appear from the C+G peaks (arrow). G6Pase enzyme assay result may be caused by insufficient or
inadequate sonification procedure for microsome disruption.
The recent cloning of the cDNA for a putative endoplas-
mic reticulum glucose-6-phosphate transporter (G6PT) (1)
has enabled the search for mutations in this gene in non GSD-
1a patients (4, 6, 10-13). Recent data from others (4, 10-13)
indicate that mutations in the SLC37A4 gene are present in
both 1b and 1c patients so far investigated. The SLC37A4
gene product is estimated to function as a transporter for a
monophosphate ester by structural comparison to various
types of bacterial monophosphate ester transporter proteins
(1). The bacterial transporter proteins as well as a human G6P
translocase have 12 transmembrane helices. The genomic
structure showed that helix 1 is in exon 1, helices 2-4 in exon
2, helices 5 and 6 in exon 3, helix 7 in exon 4, helix 8 in exon
5, helix 9 in exon 6, helix 10 and the upper region of helix
11 in exon 7, and the lower region of helix 11 and helix 12
in exon 8, indicating close correlation between transmem-
brane helices and exons (14).
Based on genome sequence data, we analyzed DNA of a
patient with GSD-1b. We identified two different mutations
in Korean patient. The first mutation at the codon 347 cause
a change in reading frame after Ala-347 and premature ter-
mination of translation in amino acid 400, which has been
previously reported in Italian family with GSD-1b (6). This
can possibly cause an abnormal folding of the transporter in
the ER membrane and, consequently, a functional anomaly.
On the other hand, nonsense mutations and insertion/deletion
mutations cause the synthesis of a truncated protein mussing
the two lysines at the carboxy-terminus necessary as a reten-
tion signal in the ER membrane and therefore do not allow
for glucose-6-phosphate transport.
The second mutation at the codon 148, novel mutation was
a missence mutation from alanine to valine at codon 148. This
alanine locates in the third transmembrane helix. This amino
acid change might alter the protein structure at the transmem-
brane region. All the known missence mutations causing amino
acid substitutions in the transmembrane region of the protein
are responsible for the conversion of a hydrophobic amino acid
to a hydrophilic amino acid. Fifty normal subjects were screened
by direct sequencing and none of them carried for the A148V
mutation in the SLC37A4 gene. To determine whether these
mutations were common to Korean GSD-1b patients, muta-
tion screening of more patients should be undertaken.
In summary, we identified a novel missence mutations in
the SLC37A4 gene in a Korean boy with the typical pheno-
type of GSD-1b, which we believe would improve our under-
standing of the genotype-phenotype correlations of SLC37A4
gene mutations. The DNA-based diagnosis of GSD-1b will
enable us to make an accurate determination of carrier sta-
tus and to perform prenatal diagnosis of this disease. To our
knowledge, this is the first report of genetically confirmed
case of GSD-1b in Koreans.
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